Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies

Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta‐analysis to evaluate the magnitude of this association and the quality of the supporting evidence.

[1]  N. Qizilbash,et al.  Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents , 2007, Pharmacoepidemiology and drug safety.

[2]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Samy Suissa,et al.  The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study , 2012, BMJ : British Medical Journal.

[4]  G. Charpentier,et al.  Earlier triple therapy with pioglitazone in patients with type 2 diabetes , 2009, Diabetes, obesity & metabolism.

[5]  Samuel M. Cohen,et al.  Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  B. Charbonnel.  Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials , 2007, Fundamental & clinical pharmacology.

[7]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[8]  B. Staels.  Metformin and pioglitazone: effectively treating insulin resistance , 2006, Current medical research and opinion.

[9]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[10]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[11]  Thomas M. MacDonald,et al.  Pioglitazone and bladder cancer: a propensity score matched cohort study. , 2013, British journal of clinical pharmacology.

[12]  N. Marchionni,et al.  Rosiglitazone and Risk of Cancer , 2008, Diabetes Care.

[13]  Elisabetta Poluzzi,et al.  Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.

[14]  R. DeFronzo,et al.  Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). , 2010, The Journal of clinical endocrinology and metabolism.

[15]  F. Alla,et al.  Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study , 2012, Diabetologia.

[16]  G. Guyatt,et al.  A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[18]  J. Miller.  FDA approves pioglitazone for diabetes. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  D. Silverman,et al.  Association between smoking and risk of bladder cancer among men and women. , 2011, JAMA.

[20]  M. Hanefeld,et al.  Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes , 2005, Diabetologia.

[21]  R. Urquhart,et al.  Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens , 2005, Diabetologia.

[22]  P. Tappenden,et al.  A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. , 2001, Clinical therapeutics.

[23]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[24]  B. Littenberg,et al.  Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System , 2007, BMC medicine.